Study of Blood Flow in Heart Muscle
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00001631 |
Recruitment Status :
Completed
First Posted : November 4, 1999
Last Update Posted : March 4, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Blood flows to areas of the heart providing oxygen and fuel to the pumping muscle. Occasionally the arteries providing the fuel can become blocked. This occurs in coronary artery disease.
Magnetic resonance imaging (MRI) can be used to evaluate the blood flow to different areas of the heart muscle. In this study magnetic resonance imaging will be compared to other diagnostic tests (radionucleotide perfusion studies) capable of measuring blood flow to heart muscle.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Coronary Disease Healthy Hypertrophic Cardiomyopathy Myocardial Ischemia | Procedure: Magnetic resonance imaging | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 249 participants |
Primary Purpose: | Treatment |
Official Title: | Study of Myocardial Perfusion by MRI |
Study Start Date : | August 1997 |
Study Completion Date : | January 2003 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
INCLUSION CRITERIA:
Ages 18 to 80.
Either sex.
Capable of giving informed consent.
Group 1: Outpatients with known or suspected coronary artery disease with clinical indication for radionuclide perfusion imaging.
Group 2: Patients with non-obstructive hypertrophic cardiomyopathy with clinical indication for radionuclide perfusion imaging.
Group 3: Normal volunteers.
Positive stress thallium or stress sestamibi (i.e., exercise, adenosine, dobutamine or dypiridamole) at the NIH.
EXCLUSION CRITERIA:
Pregnancy.
Unstable angina.
Uncontrolled hypertension (SBP greater than 185, DBP greater than 105).
Recent myocardial infarction (less than 5 days).
2nd or 3rd degree heart block by ECG.
Asthma, emphysema, renal failure, acute medical illness (fever, pneumonia, etc.) or anemia (hct less than 30).
Cardiac pacemaker or implantable defibrillator, aneurysm clip, neural stimulator, any type of ear implant, metal in your eye, any implanted device (i.e. insulin pump, drug infusion device) or any metallic foreign body, shrapnel, or bullet.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001631
United States, Maryland | |
National Heart, Lung and Blood Institute (NHLBI) | |
Bethesda, Maryland, United States, 20892 |
ClinicalTrials.gov Identifier: | NCT00001631 |
Other Study ID Numbers: |
970177 97-H-0177 |
First Posted: | November 4, 1999 Key Record Dates |
Last Update Posted: | March 4, 2008 |
Last Verified: | January 2003 |
Gadolinium Ischemia Coronary Artery Disease Hypertrophic Cardiomyopathy Dipyridamole |
Cardiomyopathies Coronary Disease Myocardial Ischemia Cardiomyopathy, Hypertrophic Ischemia Hypertrophy Pathologic Processes |
Heart Diseases Cardiovascular Diseases Vascular Diseases Pathological Conditions, Anatomical Aortic Stenosis, Subvalvular Aortic Valve Stenosis Heart Valve Diseases |